TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05809076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS
Description: tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
Study: NCT03960255

Intervention type: OTHER
Intervention: Normal standard care
Description: Both groups will receive standardized treatment and care for diabetic foot ulcers

Intervention type: OTHER
Intervention: Normal standard care
Description: Both groups will receive standardized treatment and care for diabetic foot ulcers
Study: NCT06050369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: Recording, from the scalp, the electrophysiological activity of the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: Recording, from the scalp, the electrophysiological activity of the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Get the anatomical shape of the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Get the anatomical shape of the brain.
Study: NCT04859777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT-0118
Description: MPT-0118 is an inhibitor of MALT1 protease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT-0118 + pembrolizumab
Description: MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
Study: NCT05431660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and exercise protocol about diabetic foot
Description: In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: diabetic foot school information booklet and weekly video conference meeting
Study: NCT05072782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab CT-P13
Description: Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors

Intervention type: DRUG
Group type: OTHER
Intervention: Immunosuppressors (Thiopurines or Methotrexate)
Description: Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose
Study: NCT05143021

Intervention type: OTHER
Intervention: Multidisciplinary Sickle Cell Disease- Obstetric Team
Description: Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
Study: NCT06436261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Fractional Laser
Description: A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Cleanser
Description: Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
Study: NCT05847361

Intervention type: DIAGNOSTIC_TEST
Intervention: BH4 blood level
Description: from admission to END OF PREGNANCY, a blood sample is taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: BH4 blood level
Description: from admission to END OF PREGNANCY, a blood sample is taken.
Study: NCT04859777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT-0118 + pembrolizumab
Description: MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
Study: NCT05176353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAP diagnostic stewardship bundle
Description: Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
Study: NCT04934228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5Mg Tab
Description: Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
Study: NCT05925712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroFit Seal-In Liner / Socket
Description: Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroFit Seal-In Liner / Socket
Description: Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-In Silicone Liner
Description: Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-In Silicone Liner
Description: Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
Study: NCT06351631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: 10, 15, 20, and 50 mg oral capsules
Study: NCT05039736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study: NCT06323330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech rehabilitation
Description: Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech rehabilitation
Description: Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
Study: NCT05165914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous midazolam before emergence from general anesthesia
Description: Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline before emergence from general anesthesia
Description: Intravenous administration of normal saline just before emergence from anesthesia.
Study: NCT06625060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Lyophilised powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Lyophilised powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients without active substance, Lyophilised powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients without active substance, Lyophilised powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients without active substance, Lyophilised powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients without active substance, Lyophilised powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose A
Description: Lyophilised powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose A
Description: Lyophilised powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose B
Description: Lyophilised powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose B
Description: Lyophilised powder
Study: NCT06684626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
Study: NCT04878757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CFI - Classwide Fraction Intervention
Description: 40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
Study: NCT05976633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole white rice (control)
Description: One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole brown rice
Description: One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wild rice
Description: One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Wild rice and 85% Brown rice blend - Stovetop
Description: One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
Study: NCT05101642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Creeping Technique (GCT)
Description: Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
Study: NCT05522452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face rehabilitation
Description: Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
Study: NCT06260813

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiography
Description: X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiography
Description: X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-scan
Description: CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-scan
Description: CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
Study: NCT05158608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Study: NCT06199336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHM03
Description: Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
Study: NCT05976633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Wild rice and 85% Brown rice blend - Microwaved
Description: One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
Study: NCT06377748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Description: Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
Study: NCT04474925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Surgery
Description: Surgery to remove brain metastases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Surgery
Description: Surgery to remove brain metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: SRS uses many focused radiation beams to treat tumors within the brain

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: SRS uses many focused radiation beams to treat tumors within the brain
Study: NCT06282835

Intervention type: DRUG
Intervention: Eravacycline Injection
Description: Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
Study: NCT05943795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administration by intravenous infusion
Study: NCT05985291

Intervention type: COMBINATION_PRODUCT
Intervention: SCS in combination with CMM
Description: Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
Study: NCT05482386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Description: Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
Study: NCT06377748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined facilitated tucking and ShotBlocker
Description: Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
Study: NCT06179446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pdmFlu vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pdmFlu vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pdmFlu vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: Intramuscular injection
Study: NCT06684626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Treatment typically involves fluoroquinolones alone, such as levofloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Treatment typically involves fluoroquinolones alone, such as levofloxacin.